Now Enrolling Patients with Recurrent Anaplastic Astrocytoma (rAA) Brain Cancer

Complete the form below to see if you or a loved one may qualify.


Are you eligible?

You may be eligible if:

  • Your doctor has told you that you have anaplastic astrocytoma (AA)

  • You have already been treated with radiation and a chemotherapy drug called temozolomide (also known as Temodar®)

  • Your doctor has told you that the tumor has recurred (come back) or has progressed (grown or changed) within the past 6 months

  • You completed radiation therapy more than 6 months ago 

  • You are an adult over the age of 18 years old

Travel Expenses

Participants may be eligible for study-related travel reimbursement.

What is the STELLAR study?

Brain cancer experts are conducting the STELLAR study to evaluate the use of eflornithine oral investigational medicine for treating recurrent anaplastic astrocytoma (rAA).

Eflornithine is an investigational product. An investigational product is one that has not been proven to be safe and effective for this use and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.Participation details

Study Locations

Recruiting participants at selected medical centers in the United States, Belgium, Canada, Germany, Italy, France, United Kingdom and the Netherlands.


  • Should be Empty:

For more information about the STELLAR study on the United States Government Clinical Study Registry. To find information about the STELLAR study in the European Union Clinical Study Register.

Member Login
Welcome, (First Name)!

Forgot? Show
Log In
Enter Member Area
My Profile Not a member? Sign up. Log Out